Javier San - Nov 19, 2021 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Medical Officer
Signature
/s/Javier San Martin
Stock symbol
ARWR
Transactions as of
Nov 19, 2021
Transactions value $
-$1,351,589
Form type
4
Date filed
11/22/2021, 03:56 PM
Next filing
Nov 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$946K -13.7K -10.5% $69.01 117K Nov 19, 2021 Direct F1, F2
transaction ARWR Common Stock Sale -$399K -5.7K -4.88% $70.01 111K Nov 19, 2021 Direct F1, F3
transaction ARWR Common Stock Sale -$7.1K -100 -0.09% $70.99 111K Nov 19, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.
F2 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.54 to $69.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.54 to $70.36, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.